Oncolytics Biotech (TSE:ONC) Stock Passes Above 200 Day Moving Average - Should You Sell?

Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$1.43 and traded as high as C$1.78. Oncolytics Biotech shares last traded at C$1.70, with a volume of 346,058 shares.

Analyst Ratings Changes

Separately, Raymond James raised their target price on Oncolytics Biotech from C$3.00 to C$3.50 in a research note on Friday, September 20th.

Oncolytics Biotech Stock Performance

The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The stock has a market capitalization of C$132.20 million, a P/E ratio of -4.47 and a beta of 1.35. The business has a 50-day moving average price of C$1.36 and a 200 day moving average price of C$1.43.

Oncolytics Biotech (TSE:ONC - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported C($0.10) EPS for the quarter, meeting the consensus estimate of C($0.10). As a group, sell-side analysts forecast that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.